Literature DB >> 22812387

Early treatment response evaluated by a clinical scoring system correlates with the prognosis of pulmonary tuberculosis patients in Ethiopia: a prospective follow-up study.

Helena Janols1, Ebba Abate, Jonna Idh, Meseret Senbeto, Sven Britton, Shitaye Alemu, Abraham Aseffa, Olle Stendahl, Thomas Schön.   

Abstract

BACKGROUND: In resource-limited settings the monitoring of tuberculosis (TB) patients is challenging, and early identification of TB patients with a high mortality risk is important. The aim of this study was to investigate prospectively whether early changes in a clinical scoring system (TB score) can predict treatment outcome in Ethiopian patients with pulmonary tuberculosis.
METHOD: TB patients (n = 250) and blood donors (n = 82) were recruited prospectively at Gondar University Hospital, Ethiopia. Clinical scoring was performed using an interview-based questionnaire and clinical examination.
RESULTS: Among TB patients (53.6% of whom were HIV co-infected) the median TB score declined from week 0 to week 2 (8 (interquartile range (IQR) 6-9) vs 4 (IQR 2-6)) and dropped to a low level at week 8, which was still significantly higher than that found in blood donors (2 (IQR 1-4) vs 0 (IQR 0-1), p < 0.0001). Patients who died had a significantly higher TB score at week 0, week 2, and week 8 than survivors. Mortality was associated with a failure to achieve a decrease greater than 25% in the TB score at 2 weeks. Baseline CD4 + cell counts (< 200 cells/mm³) were associated with mortality but not with initial TB score results.
CONCLUSIONS: The TB score was increased during the first 2 months of treatment among patients who died. Failure to achieve a greater than 25% decrease in TB score after 2 weeks of treatment was associated with increased mortality. Repeated clinical scoring during the intensive phase of TB treatment could be useful to identify high-risk patients.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22812387     DOI: 10.3109/00365548.2012.694468

Source DB:  PubMed          Journal:  Scand J Infect Dis        ISSN: 0036-5548


  9 in total

1.  Daily adjunctive therapy with vitamin D3 and phenylbutyrate supports clinical recovery from pulmonary tuberculosis: a randomized controlled trial in Ethiopia.

Authors:  A Bekele; N Gebreselassie; S Ashenafi; E Kassa; G Aseffa; W Amogne; M Getachew; A Aseffa; A Worku; R Raqib; B Agerberth; U Hammar; P Bergman; G Aderaye; J Andersson; S Brighenti
Journal:  J Intern Med       Date:  2018-05-23       Impact factor: 8.989

2.  Helminth species specific expansion and increased TNF-alpha production of non-classical monocytes during active tuberculosis.

Authors:  Gezahegn Bewket; Amare Kiflie; Ebba Abate; Olle Stendahl; Thomas Schön; Robert Blomgran
Journal:  PLoS Negl Trop Dis       Date:  2021-03-02

Review 3.  Systematic review of prediction models for pulmonary tuberculosis treatment outcomes in adults.

Authors:  Lauren S Peetluk; Felipe M Ridolfi; Peter F Rebeiro; Dandan Liu; Valeria C Rolla; Timothy R Sterling
Journal:  BMJ Open       Date:  2021-03-02       Impact factor: 2.692

4.  The Bandim TBscore--reliability, further development, and evaluation of potential uses.

Authors:  Frauke Rudolf
Journal:  Glob Health Action       Date:  2014-05-22       Impact factor: 2.640

5.  Morphoproteomic-Guided Host-Directed Therapy for Tuberculosis.

Authors:  Robert E Brown; Robert L Hunter; Shen-An Hwang
Journal:  Front Immunol       Date:  2017-02-02       Impact factor: 7.561

6.  Delay in treatment initiation and its association with clinical severity and infectiousness among new adult pulmonary tuberculosis patients in Tigray, northern Ethiopia.

Authors:  Kiros Tedla; Girmay Medhin; Gebretsadik Berhe; Afework Mulugeta; Nega Berhe
Journal:  BMC Infect Dis       Date:  2020-06-29       Impact factor: 3.090

7.  The safety, effectiveness and cost-effectiveness of cytisine in achieving six-month continuous smoking abstinence in tuberculosis patients-protocol for a double-blind, placebo-controlled randomized trial.

Authors:  Omara Dogar; Deepa Barua; Melanie Boeckmann; Helen Elsey; Razia Fatima; Rhian Gabe; Rumana Huque; Ada Keding; Amina Khan; Daniel Kotz; Eva Kralikova; James N Newell; Iveta Nohavova; Steve Parrott; Anne Readshaw; Lottie Renwick; Aziz Sheikh; Kamran Siddiqi
Journal:  Addiction       Date:  2018-04-20       Impact factor: 6.526

8.  Asymptomatic Helminth Infection in Active Tuberculosis Is Associated with Increased Regulatory and Th-2 Responses and a Lower Sputum Smear Positivity.

Authors:  Ebba Abate; Meseret Belayneh; Jonna Idh; Ermias Diro; Daniel Elias; Sven Britton; Abraham Aseffa; Olle Stendahl; Thomas Schön
Journal:  PLoS Negl Trop Dis       Date:  2015-08-06

9.  Treatment delay affects clinical severity of tuberculosis: a longitudinal cohort study.

Authors:  J Virenfeldt; F Rudolf; C Camara; A Furtado; V Gomes; P Aaby; E Petersen; C Wejse
Journal:  BMJ Open       Date:  2014-06-10       Impact factor: 2.692

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.